Atlas and J&J fund new epigenetics start-up
This article was originally published in Scrip
Executive Summary
Rodin Therapeutics of Boston, Massachusetts, has raised $12.9m in a series A round led by founding investors Atlas Venture and Johnson & Johnson Development Corporation. Rodin is using epigenetics to develop novel therapeutics for neurological disorders.